
USD
+$0.00
(+0.00%
)At Close (As of Nov 14, 2025)
$6.13M
Market Cap
-
P/E Ratio
-8.91
EPS
$4.90
52 Week High
$0.55
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $4M |
| Total Revenue | $9.3M |
| Cost Of Revenue | $5.3M |
| Costof Goods And Services Sold | $5.3M |
| Operating Income | -$13M |
| Selling General And Administrative | $7.7M |
| Research And Development | $3.5M |
| Operating Expenses | $17M |
| Investment Income Net | - |
| Net Interest Income | -$176K |
| Interest Income | $44K |
| Interest Expense | $220K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | -$56K |
| Income Before Tax | -$12M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$12M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$13M |
| Ebitda | -$13M |
| Net Income | -$12M |
| Field | Value (USD) |
|---|---|
| Total Assets | $9.4M |
| Total Current Assets | $3.6M |
| Cash And Cash Equivalents At Carrying Value | $1.9M |
| Cash And Short Term Investments | $1.9M |
| Inventory | - |
| Current Net Receivables | $1.4M |
| Total Non Current Assets | $5.8M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $5.3M |
| Intangible Assets Excluding Goodwill | $5.3M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $0 |
| Other Current Assets | $265K |
| Other Non Current Assets | - |
| Total Liabilities | $6M |
| Total Current Liabilities | $5.8M |
| Current Accounts Payable | $4.2M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $43K |
| Total Non Current Liabilities | $269K |
| Capital Lease Obligations | $312K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $312K |
| Other Current Liabilities | $1.2M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $3.3M |
| Treasury Stock | - |
| Retained Earnings | -$72M |
| Common Stock | $170 |
| Common Stock Shares Outstanding | $711K |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$8.3M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $2.3M |
| Capital Expenditures | $57K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $2M |
| Cashflow From Financing | $5.8M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$12M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $4M |
| Total Revenue | $9.3M |
| Cost Of Revenue | $5.3M |
| Costof Goods And Services Sold | $5.3M |
| Operating Income | -$13M |
| Selling General And Administrative | $7.7M |
| Research And Development | $3.5M |
| Operating Expenses | $17M |
| Investment Income Net | - |
| Net Interest Income | -$176K |
| Interest Income | $44K |
| Interest Expense | $220K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | -$56K |
| Income Before Tax | -$12M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$12M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$13M |
| Ebitda | -$13M |
| Net Income | -$12M |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
iSpecimen Inc. is a pioneering technology company headquartered in Lexington, Massachusetts, that revolutionizes the procurement of human biospecimens for life science research. By connecting researchers with a vast network of healthcare providers, iSpecimen specializes in sourcing essential biofluids, tissues, and living cells, meeting the increasing demand for high-quality specimens in the biomedical sector. Its innovative platform streamlines the biospecimen acquisition process, thereby expediting scientific research and fostering significant advancements in healthcare and clinical trials, positioning iSpecimen as a vital partner for researchers worldwide.